

SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by the
Yale Center for Immuno-Oncology



YaleCME
CONTINUING MEDICAL EDUCATION

“Steroid hormone signaling alters CD8+ T cell differentiation in the tumor microenvironment”

Speaker:

Ana Anderson, PhD

Associate Professor of Neurology, Harvard Medical School and Associate Scientist, Department of Neurology, Brigham and Women’s Hospital

Tuesday, February 4, 2020

4:00 – 5:00pm

TAC N-107

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Understand the different subpopulations of CD8+ TILs present in the tumor microenvironment and how to identify them.
2. Understand the steroid biosynthesis pathway and specifically glucocorticoid biosynthesis.
3. Understand how glucocorticoids impact on CD8+ T cell phenotype

in the tumor microenvironment.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Ana Anderson: Has served as an SAB consultant for Tizona Therapeutics, Compass Therapeutics and Zumutor Biologics.

Stephanie Eisenbarth: None

Carrie Lucas: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

There is no corporate support for this activity

Seminar Host: Marcus Bosenberg, MD, PhD

Course Directors: Stephanie Eisenbarth, MD, PhD and Carrie Lucas, PhD

For additional information, please contact Allysia Matthews (allysia.matthews@yale.edu)